

Notice of Allowability**Application No.**

09/840,503

Applicant(s)

IWANOWICZ ET AL.

Examiner

Hong Liu

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed on March 25, 2004.
2. ☒ The allowed claim(s) is/are 10,12-23,30-35 and 37-41.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Laurelee Duncan on 05/05/04.

The application has been amended as follows:

In claim 30, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 31, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 32, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

Art Unit: 1624

In claim 33, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 34, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 38, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 39, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".

After "administering ", insert --to a subject--.

In claim 40, second line, after associated disorders", insert selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simple II, rheumatoid arthritis, asthma, and transplant rejection".


After "administering ", insert --to a subject--.

Art Unit: 1624

Any inquiry concerning this communication should be directed to Examiner Hong Liu whose telephone number is (571) 272-0669. The examiner can normally be reached on Monday through Friday from 8:30 AM to 6:00 PM.

If attempts to reach the examiner by the phone are unsuccessful, the examiner's supervisors, Mukund Shah can be reached at (571) 272-0674. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 358-1235.



RICHARD L. RAYMOND
PRIMARY EXAMINER
ART UNIT 1624

Mukund Shah
Supervisory Patent Examiner
Art Unit 1624

hl
May 5, 2004